-
Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer
•
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global pivotal Phase II clinical study (S7300-127) assessing the efficacy and safety of its DS7300 (DS7300a), a potential first-in-class antibody drug conjugate (ADC), in patients with extensive small-cell lung cancer (SCLC) in China. DS7300 is an…
-
Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a Phase III clinical study for its Category 1 drug, ABSK021. The randomized, double-blind, placebo-controlled, multi-center Phase III study is designed to assess the efficacy and…
-
Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China
•
China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel coronavirus fusion protein vaccine, V-01. The vaccine was first administered as a sequential booster shot in Guangdong on September 21. V-01 is being co-developed by Livzon subsidiary Zhuhai Livzon Monoclonal Antibodies Biotechnology Co., Ltd and…
-
Venmedtech Raises Series B+ Funding for Iliac Vein Stent and Product R&D
•
Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of renminbi in a Series B+ financing round. The funding was contributed by Qiao Jing Capital and Zhuopu Venture Capital. Proceeds from the financing will be directed towards market promotion of the company’s Iliac vein stent…
-
Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development
•
China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A financing round, raising RMB 100 million (USD 13.68 million). The round was led by Vivo Capital. The proceeds will be directed toward the research and development of Celgenyx’s next-generation off-the-shelf cell therapy. Current Landscape of…
-
Easy-Flow Medical Secures Angel Funding for Peripheral Device Development
•
China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by Legend Capital, with participation from Shanghai Xinyue Jiupeng Enterprise Consulting Center. The proceeds will be allocated toward the research and development…
-
Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a Phase Ib/II clinical study in China for its SHR-A1811 combined with SHR-1701 in patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ). This approval marks a significant step forward in the development of…
-
Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing
•
China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised over RMB 100 million (USD 13.7 million) in a Series C+ financing round. The round was led by Oct. Capital, with participation from Momentum Venture and Chang An Hui Tong, alongside returning investor Yinglian Health…
